BeyondSpring Inc. (BYSI)
Nasdaq · Healthcare · Biotechnology
$0.786−0.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $32.3M
- 52-week range
- $0.566 – $2.44
- 52-week change
- −56.16%
- EPS (trailing)
- −$0.18
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$1.0M
- Free cash flow
- −$19.8M
From the company’s annual report on SEC EDGAR.
About BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
Headquarters: Florham Park, United States · 44 employees · beyondspringpharma.com